drug_type
RELEVANT_DRUG
intervention_type
Vaccine (recombinant viral vector)
drug_description
Recombinant vaccinia viral vector vaccine expressing HPV16/18 E6/E7 tumor antigens used as a boost to enhance HPV-specific immune responses.
nci_thesaurus_concept_id
C2403
nci_thesaurus_preferred_term
Human Papillomavirus Tumor Antigen Vaccine
nci_thesaurus_definition
A vaccinia viral based vaccine, encoding epitopes of E6 and E7 proteins from human papillomavirus (HPV) types 16 and 18, with immunostimulatory and antineoplastic activities. HPV types 16 and 18 account for approximately 70% of cervical cancers. Vaccination with this HPV-TA (tumor antigen) vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for E6 and E7 from either type 16 or 18 HPV, resulting in decreased tumor growth.
drug_mesh_term
human papillomavirus vaccine
drug_category
VIRAL VECTOR VACCINE
drug_class
Vaccine
drug_delivery_route
Intramuscular
drug_mechanism_of_action
Recombinant vaccinia viral vector that delivers and expresses HPV16/18 E6/E7 tumor antigens in host antigen-presenting cells, leading to MHC I/II presentation and induction of HPV-specific CD8+ cytotoxic and CD4+ helper T-cell responses that target and kill E6/E7-expressing tumor cells; used as a boost to enhance HPV-directed immunity.
drug_name
TA-HPV
nct_id_drug_ref
NCT05799144